Today we take a short break from our AACR conference coverage and look at some creative new research that has its roots in oncology, i.e. antibody drug conjugates (ADCs), while being adapted and adopted for use in microbiology and infectious diseases. Here at BSB, we have always been attracted to innovative science and technology and this latest project certainly fits that bill.
This is not such a stretch as many may think, after all, advanced cancer patients or those in an ICU tend to be prone to infectious complications, which can, unfortunately, be lethal.
While this work is currently ongoing in the preclinical setting, it could be something we hear a lot more about in the near future as clinical development rolls out and there is a dramatic impact for patients.
Curious as to what all the fuss is about?
Subscribers can learn more by logging in or you can subscribe via the blue box below: